

SWOG Trial Support

Application

SWOG Trial Support (STrS) is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support qualified trial components that occur during the time of patient enrollment to avoid delay of trial activation or, in some cases, to ensure real-time collection of additional critical data.

Qualifying trial components may include those that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, provision of materials to trial sites, or PROs.

In most instances, qualifying applications will fund core trial components or **integral** biomarkers and TM-related work. However, to further support critically important TM that is not funded by industry, and that has been previously submitted and denied to BIQSFP, the review committee will consider funding **integrated** biomarkers. Integrated biomarkers that are included for support under this mechanism must be highly likely to inform future SWOG protocols, demonstrating strong potential to ultimately impact SWOG patients.

STrS funding is **not intended for salary support of Principal Investigators or Co-PIs**.

APPLICATION PROCESS

Submissions are expected at the time of submission of the SWOG clinical trial capsule for Executive Review at triage; although, if a need is identified after that time – but during the period of patient enrollment – an application may be reviewed independently of the ERC.

- Principal Investigators for SWOG trials should be the named applicant.
- Suitability of the funding request must be reviewed by the appropriate Committee Chair and Executive Officer prior to submission.
- Review of an STrS request will occur during Executive Review alongside the capsule and Translational Medicine assessments.

REVIEW PROCESS

Applications will receive a summary score, which will be used to determine if a project is funded. This is based upon the following criteria:

1. **Impact Score** of the parent clinical trial
2. **Significance** of the STrS component to the trial overall

OTHER FUNDING

As appropriate, investigators should apply for other sources of funding such as R01, BIQSFP, or industry funding, and if successful, there should be **no overlap with STrS**.

If an investigator obtains other funding (e.g., NIH or industry funds), the awarded STrS funds may be made available to support other projects.

NOTIFICATION OF AWARD

Notification of funding will typically occur simultaneously with Executive Review approval of the project; however, if at year's end there are unexpended funds, previously reviewed but unfunded applications may become eligible for an STrS award.

Upon request, The Hope Foundation will write a letter of financial support to be submitted with the Concept to the NCTN Steering Committee.

Award amount: Up to \$75,000/year; 1 or 2 years (total cost)

Award period: Ongoing

APPLICATION FORM

Submission documents:

- STrS application form (3 pages)
- Budget and justification (Use Hope [budget template](#))

Parent study title:

Today's date:

Expected date of SWOG Executive Review:

Study chair:

Committee:

Committee Chair approval date:

Executive Officer:

Executive Officer approval date:

Date of BIQSFP negative response (if applicable):

Total funding requested (note: per Foundation policy, IDC is limited to 25%):

Year 1:

Year 2:

DESCRIPTION OF REQUEST

Within the space provided below, please summarize the project requiring STrS funding and its relationship to the parent SWOG study. Include an explanation of the need for funding, whether or not other funding is being sought for the project, and/or why it is not eligible for other funding mechanisms.
(The relevant component of the trial, along with statistical analysis if applicable, should be fully described in the accompanying SWOG capsule or translational medicine form.)